By PPN News Staff
The FDA approved daprodustat (Jesduvroq, GSK) as the first oral treatment for anemia caused by chronic kidney disease (CKD) in adults on dialysis.
The FDA approval of daprodustat, an oral hypoxia-inducible factor–prolyl hydroxylase inhibitor (HIF-PHI), is based on results from the ASCEND-D trial, assessing the efficacy and safety of daprodustat to treat anemia of CKD in patients on dialysis (N Engl J Med 2021;385:2325-2335). The ASCEND program included five phase 3